Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa plus gemcitabine/cisplatin vs placebo plus gemcitabine/cisplatin in first-line biliary tract cancer
jRCT2080224877Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in biliary cancer comparing Bintrafusp alfa + gemcitabine/cisplatin with Placebo + gemcitabine/cisplatin (2 arms). Started Sep 2019; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
biliary cancer
Beyond the preview
Go deeper on jRCT2080224877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224877.